Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Historically the beginnings of pharmacogenetics could be located in the late 1950. At that time, a genetic explanation was found to possibly explain the therapeutic or side effects of certain drugs. The objective of the clinical pharmacogenetics is to distinguish patients who could respond more or Jess to a treatment (choice of drug and I or dose). In this work, we propose to review the involvement of pharmacogenetics in the treatment of two autoimmune diseases as psoriasis and lupus. According to the literature the pharmacogenetic study would be of interest in the case of the lupus about the azathioprine and the mycophenolate mofétyl. As is psoriasis of such studies are of interest for the methotrexate, calcineurin inhibitors and TNF-a inhibitor. Les débuts de la pharmacogénétique sont situés historiquement à la fin des années 1950. A cette époque, une explication génétique fut mise en évidence quant aux effets thérapeutiques ou indésirables de certains médicaments. L'objectif de la pharmacogénétique clinique est de distinguer les patients plus ou moins répondants en sorte de pouvoir adapter au mieux le traitement (choix du médicament et/ou de la dose). Dans ce travail, nous proposons de faire le point sur l'implication de la pharmacogénétique dans le traitement de deux pathologies auto-immunes qui sont le psoriasis et le lupus. D'après la bibliographie concernant le lupus l'azathioprine et le mycophénolate de mofétyl seraient d'intérêt pour des études pharmacogénétiques. En ce qui est le psoriasis des telles études sont d'intérêt pour la méthotrexate, les inhibiteurs de la calcineurine et les inhibiteurs de TNF-a.

Pharmacogenetics --- Psoriasis --- Lupus Erythematosus, Cutaneous --- Lupus Erythematosus, Discoid

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Quatrième de couverture : "Le lupus érythémateux systémique (LED) est une maladie auto-immune avec une implication de plusieurs organes, plus de la moitié des patients atteints de LED développent un lupus néphrétique au cours de la progression de leur maladie. Les vascularites associées aux ANCA (AAV) sont un groupe de maladies auto-immunes systémiques qui affectent les vaisseaux de petite et moyenne taille. Le lupus érythémateux disséminé et la vascularite des petits vaisseaux sont habituellement deux maladies auto-immunes distinctes. La présence d'ANCA, en particulier de c-ANCA dans le LED, n'est pas fréquente. Nous signalons un cas de LED associé au c-ANCA. Notre objectif est de discuter de la signification clinique, du mécanisme étiopathogène et de la prise en charge de cette association. Ce livre s'adresse à un large public de médecins."

Lupus Erythematosus, Systemic --- Lupus Nephritis --- Lupus Erythematosus, Cutaneous --- Lupus Erythematosus, Discoid --- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Lupus Erythematosus, Systemic --- Systemic lupus erythematosus --- Lupus érythémateux disséminé --- Lupus Erythematosus, Cutaneous --- Lupus Erythematosus, Discoid --- Autoimmune Diseases --- Lupus érythémateux disséminé --- Lupus Erythematosus, Systemic.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Systemic lupus erythematosus (S.L.E.), commonly called lupus, is a chronic autoimmune disorder that can affect virtually any organ of the body. In lupus, the body's immune system, which normally functions to protect against foreign invaders, becomes hyperactive, forming antibodies that attack normal tissues and organs, including the skin, joints, kidneys, brain, heart, lungs, and blood. Lupus is characterized by periods of illness, called flares, and periods of wellness, or remission. Because its symptoms come and go and mimic those of other diseases, lupus is difficult to diagnose. There is no single laboratory test that can definitively prove that a person has the complex illness. To date, lupus has no known cause or cure. Early detection and treatment is the key to a better health outcome and can usually lessen the progression and severity of the disease. Anti-inflammatory drugs, anti-malarials, and steroids (such as cortisone and others) are often used to treat lupus. Cytotoxic chemotherapies, similar to those used in the treatment of cancer, are also used to suppress the immune system in lupus patients. A new edition of this established and well regarded reference which combines basic science with clinical science to provide a translational medicine model. Systemic Lupus Erythematosus is a useful reference for specialists in the diagnosis and management of patients with SLE, a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease and a reference work for hospital libraries. * Highly illustrated and in full color throughout * Basic science section expanded to allow the reader to focus on the newest techniques in molecular medicine and its effects on disease expression and treatment * Clinical aspects and new drugs will be covered in great detail providing a useful reference to both experienced clinicians and physicians with an interest in lupus in their clinical practice.

Systemic lupus erythematosus. --- Lupus Erythematosus, Cutaneous --- Lupus Erythematosus, Systemic --- Antiphospholipid Syndrome --- Lupus Erythematosus, Systemic. --- Libman-Sacks Disease --- Lupus Erythematosus Disseminatus --- Systemic Lupus Erythematosus --- Disease, Libman-Sacks --- Libman Sacks Disease --- Libman-Sacks disease --- Lupus (Systemic lupus erythematosus) --- Lupus erythematosus, Systemic --- Lupus erythematosus disseminatus --- SLE (Disease) --- Autoimmune diseases --- Blood-vessels --- Collagen diseases --- Skin --- Diseases